Real-world evidence positions nirsevimab ahead in infant RSV prevention
Respiratory syncytial virus (RSV) remains a leading cause of hospitalisation and severe lower respiratory tract infection (LRTI) in infants worldwide. [Lancet 2022;399:2047-2064; Lancet 2017;390:946-958] In recent years, two immunoprophylactic strategies have become available to protect infants, namely maternal immunisation with the RSV prefusion F (RSVpreF) vaccine and passive immunisation of infants with the long-acting monoclonal antibody nirsevimab.